Evidence map›Paper›PMID 40881929›Full record

ReviewEXCLI journal2025

The impact of artificial intelligence on drug discovery for neuropsychiatric disorders.

Vickram Agaram Sundaram, Bharath Saravanan, Bhavani Sowndharya Balamurugan, Mathan Muthu Chinnakannu Marimuthu, Kavita Munjal, Hitesh Chopra

Abstract readReview
In one paragraph

Review in EXCLI journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vickram Agaram SundaramDepartment of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai, 602105, India.
Bharath SaravananDepartment of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai, 602105, India.
Bhavani Sowndharya BalamuruganDepartment of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai, 602105, India.
Mathan Muthu Chinnakannu MarimuthuDepartment of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai, 602105, India.
Kavita MunjalAmity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India.
Hitesh ChopraCentre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) and machine learning (ML) are transforming medication discovery, particularly in neuropsychiatric illnesses, where traditional drug research presents major obstacles. This paper looks at how artificial intelligence might help advance neuropsychiatric medication development, with an emphasis on early-stage research, drug design, and clinical diagnostics. This review discusses AI's contribution to understanding the blood-brain barrier and its link with the central nervous system, which is an important aspect of medication efficacy in neuropsychiatric treatments. AI-facilitated de novo drug design, using predictive algorithms and deep learning models, speeds up the discovery of new medicinal molecules. AI is employed in brain imaging and diagnosis, boosting the accuracy with which neuropsychiatric diseases are identified. BBB permeability prediction is one of the most important uses of AI in drug discovery, as it improves the selection of CNS-active drugs. Additionally, AI is transforming treatment techniques for neurodevelopmental disorders and assisting in the discovery of novel antidepressant medications through data-driven methodologies. Despite these accomplishments, AI-driven drug discovery still has several constraints, such as data biases, regulatory barriers, and ethical issues. Overcoming these restrictions will be critical to unlocking AI's full potential in neuropsychiatric research. This paper concludes with several future possibilities and opportunities, such as incorporating AI into personalized medicine using sophisticated neural network models and multimodal data fusion techniques. This might increase treatment choices for certain conditions by fine-tuning AI approaches. This paper presents a perspective on AI as a highly transformative instrument for influencing neuropsychiatric drug development, as well as an emerging field that has the potential to impact the modern idea of pharmacology. See also the graphical abstract(Fig. 1).

Indexed as

AI-driven drug developmentArtificial Intelligenceblood-brain barriermachine learningneuropsychiatric disorders

Identifiers

PMID40881929
PMCPMC12381367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.